FRACTALE Corporation (TSE:3750) agreed to acquire the remaining 43.63% stake in Cytori Therapeutics inc from HG Capital, The Conscious Group Ltd, Toshiyasu Horie, Tokyo Weld Co., Ltd. and Capital Medica Co.Ltd. for ¥2.1 billion on May 15, 2020. Under the term, FRACTALE will acquire Cytori for an exchange ratio of 1,038. Post completion, Cytori will operate as a wholly-owned subsidiary of FRACTALE. As of December 31, 2019, Cytori reported sales of ¥174 million, operating loss of ¥184 million and net loss of ¥197 million. The transaction is subject to FRACTALE and Cytori shareholder approval. The transaction is expected to close on July 7, 2020. Maxus Corporate Advisory Inc. acted as a financial advisor and Hibiya Park Law Office acted as a legal advisor to FRACTALE. FRACTALE Corporation (TSE:3750) canceled the acquisition of Cytori Therapeutics inc from HG Capital, The Conscious Group Ltd, Toshiyasu Horie, Tokyo Weld Co., Ltd. and Capital Medica Co.Ltd. on May 15, 2021.